What's Happening?
Biohub, a non-profit research organization co-founded by Priscilla Chan and Mark Zuckerberg, has released an updated version of the ESM protein language model family. This model, known as ESMC, is designed to enhance binder design and protein function
mapping, which are crucial for therapeutic discovery. The model is trained on approximately 2.8 billion sequences from various life forms, including those adapted to extreme environments. It aims to transform drug discovery by making biology more programmable, potentially accelerating development timelines. The model's capabilities were showcased at the 'AI in Biology' symposium at Cold Spring Harbor Laboratory. ESMFold2, a component of the model, has successfully designed high-affinity protein binders for cancer and immunology targets, demonstrating potential clinical utility.
Why It's Important?
The release of the ESM protein language model by Biohub represents a significant advancement in the field of protein biology and drug discovery. By enabling more accurate digital representations of proteins, the model allows researchers to ask experimental questions at a scale previously impossible in traditional laboratory settings. This could lead to faster and more efficient drug development processes, reducing the time and resources typically required. The model's open-source availability under the MIT license ensures that it can be widely used by researchers and companies, potentially accelerating innovation in therapeutic development. The initiative aligns with Biohub's broader goal of advancing virtual biology and building predictive models of biological systems.
What's Next?
Biohub plans to continue its efforts in virtual biology by investing in the Virtual Biology Initiative, a five-year campaign aimed at creating technologies and datasets for predictive biological models. The organization is also collaborating with partners like Arc Institute and Tahoe Therapeutics to build extensive datasets for virtual cell research. These efforts are expected to further enhance the capabilities of the ESM models and support the development of new therapeutic strategies. The ongoing research and collaborations indicate a commitment to leveraging AI and computational models to address complex biological challenges.
